New NYU Langone trial shows role of drug + CI-PCM care in Alzheimer's
A new trial conducted by NYU Langone Medical Centre in the US has demonstrated a favourable outcome with the combination of a common Alzheimer's disease drug and a specific care management programme. (Source: Drug Development Technology)
Source: Drug Development Technology - July 17, 2017 Category: Pharmaceuticals Source Type: news
Wave Life Sciences begins Phase Ib/IIa trials of two Huntington ’s disease drugs
Wave Life Sciences has begun new Phase Ib/IIa clinical trials (PRECISION-HD1 and PRECISION-HD2) of WVE-120101 and WVE-120102 to treat patients suffering with Huntington ’s disease (HD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 17, 2017 Category: Pharmaceuticals Source Type: news
Apexigen starts dosing in Phase Ib/II combination trial for solid tumours
Apexigen has started dosing patients in a Phase Ib/II clinical trial of APX005M in combination with Bristol-Myers Squibb ’s Opdivo (nivolumab) to treat patients with advanced solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - July 17, 2017 Category: Pharmaceuticals Source Type: news
Halozyme initiates Phase Ib/II oncology combination trial
US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 16, 2017 Category: Pharmaceuticals Source Type: news
Innovation reports positive top-line results from Phase II trial of IBD drug
Innovation Pharmaceuticals has reported positive top-line results from a Phase II clinical trial of brilacidin in patients with inflammatory bowel disease (IBD) types known as ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). (Source: Drug Development Technology)
Source: Drug Development Technology - July 16, 2017 Category: Pharmaceuticals Source Type: news
Foundation Medicine to support enrolment for Kura Oncology ’s SCCHN trials
US-based biopharmaceutical firm Kura Oncology has signed a collaboration agreement with Foundation Medicine to support patient enrolment into its clinical programme of tipifarnib to treat relapsed and / or refractory HRAS mutant squamous cell carcino … (Source: Drug Development Technology)
Source: Drug Development Technology - July 16, 2017 Category: Pharmaceuticals Source Type: news
Huge New Opportunity in Generic Drug Development Created by US FDA
The US market is to gain access to previously unavailable therapeutically equivalent generic drug formulations due to a number of changes. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news
Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: MyoKardia, Kala Pharmaceuticals, Mesoblast
MyoKardia has announced plans to issue more than nine million shares of its common stock priced at $13.3 a share, to raise $122.15m in gross proceeds. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news
Abivax reports positive data from ABX464 study for HIV-related inflammation
French biotechnology firm Abivax has reported positive findings from the evaluation of the ability of its product candidate ABX464 to mitigate intestinal inflammation in HIV patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news
VBI Vaccines to study Sci-B-Vac in Phase III programme for hepatitis B
US-based VBI Vaccines is set to evaluate its third-generation hepatitis B vaccine Sci-B-Vac in a global Phase III clinical programme after positive discussions with the US Food and Drug Administration (FDA), Health Canada and the European Medicines A … (Source: Drug Development Technology)
Source: Drug Development Technology - July 12, 2017 Category: Pharmaceuticals Source Type: news
Haegarda for the Preventive Treatment of Hereditary Angioedema
Haegarda ® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 12, 2017 Category: Pharmaceuticals Source Type: news
Vifor Pharma studies Ferinject in three trials for heart failure and iron deficiency
Swiss-based Vifor Pharma has initiated three clinical trials known as AFFIRM-AHF, FAIR-HF2 and HEART-FID, to assess the efficacy of Ferinject on morbidity and mortality outcomes in systolic heart failure and iron deficiency patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 12, 2017 Category: Pharmaceuticals Source Type: news
Valerion starts VAL-1221 dosing in Phase I/II trial for Pompe disease
Valerion Therapeutics has started dosing patients in a Phase I/II clinical trial of VAL-1221 to treat patients suffering from late-onset Pompe disease. (Source: Drug Development Technology)
Source: Drug Development Technology - July 12, 2017 Category: Pharmaceuticals Source Type: news
BioLineRx to study BL-8040 in Phase Ib/II trial for pancreatic cancer treatment
Israeli company BioLineRx has started a Phase Ib/II clinical trial of its BL-8040 in combination with Roche Group subsidiary Genentech's atezolizumab (Tecentriq) to treat pancreatic cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 11, 2017 Category: Pharmaceuticals Source Type: news
